What a court win says about India’s generics case
Risdiplam is the life-saving drug for a rare disease, Spinal Muscular Atrophy (SMA). Costing Rs 6L per bottle, it will now be available for less than Rs 16,000 per bottle. Because the Supreme Court has refused to intervene in a high court judgment, which upheld Indian generic manufacturer Natco’s challenge to the validity of the Risdiplam patent, held by the multinational pharma company Roche.
Read full story on TOI+
Disclaimer
Views expressed above are the author’s own.
END OF ARTICLE
